Search
Thursday 18 June 2015
  • :
  • :

Thursday’s Active Stocks: SeaDrill Limited, (NYSE:SDRL), Juno Therapeutics, (NASDAQ:JUNO), Baidu, (NASDAQ:BIDU)

During Thursday’s Morning trade, Shares of SeaDrill Limited (NYSE:SDRL), lost -4.25% to $10.81, despite oil prices rose on Thursday as a weaker dollar made fuel cheaper for holders of other currencies, and on hopes of a last-minute breakthrough that could keep Greece in the euro zone and assist avoid a shock to European economic growth.

The dollar fell 0.65 percent to a one-month low against a basket of currencies .DXY after the Federal Reserve disappointed investors who had hoped for a clearer signal on when the U.S. central bank will lift interest rates, according to Reuters.

Seadrill Limited, an offshore drilling contractor, provides offshore drilling services to the oil and gas industry worldwide. The company operates through Floaters and Jack-up Rigs segments.

Shares of Juno Therapeutics Inc. (NASDAQ:JUNO), inclined 5.05% to $53.92, during its current trading session.

Juno Therapeutics, might not be turning a profit yet, but that’s no problem for CEO Hans Bishop’s personal bottom line, according to American City Business Journals.

Bishop is the 11th highest-paid CEO in the country, according to Bloomberg’s Pay Index, a daily ranking of the 100 top-paid executives. His pay package was worth $88.2 million at the end of 2014, Bloomberg stated Thursday, in a combination of salary, stock options and restricted shares. That was worth $7.3 million before Juno’s initial public offering in December. American City Business Journals Reports.

Juno isn’t the only biotech to show up near the top of the list. CEO pay at Santa Monica, Calif.-based Kite Pharma and Waltham, Mass.-based Radius Health Inc. topped $95 million and $33.5 million, respectively. American City Business Journals added.

Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.

Finally, Baidu, Inc. (NASDAQ:BIDU), gained 0.09%, and is now trading at $209.69.

iQIYI, an independently operated partner of Baidu, and one of the largest internet and mobile video service providers in China, declared that the company’s paid streaming subscribers have reached five million as of June 15, 2015, a 765% annual enhance.

iQIYI’s paid subscription provides a wide range of premium content to members. In 2014, iQIYI hosted over 60% of the movies played in cinemas in China. Over 80% of movies whose box office income exceeded 100 million RMB in China in 2014 can be found on iQIYI, together with over 400 internet-only movies.

In the future, iQIYI will continue to provide more excellent domestic and international content to members. In 2015, iQIYI plans to acquire about a thousand titles from Hollywood.

iQIYI, launched on April 22, 2010, is an independently operated partner of Baidu, the world’s largest Chinese search engine. Since its launch, iQIYI has pursued the ultimate online video experience for Chinese users, becoming an industry model in promoting innovation in products, technologies, and marketing.

Baidu, Inc. provides Internet search services in China and internationally. It offers Chinese language search platform on its Baidu.com Website that enables users to find relevant information online, counting Web pages, news, images, documents, and multimedia files through links offered on its Website; and international products and services to users in other countries.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.




Leave a Reply

Your email address will not be published. Required fields are marked *